IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 51.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 953 shares of the company's stock after selling 1,023 shares during the period. Snowden Capital Advisors LLC's holdings in IDEXX Laboratories were worth $394,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Geode Capital Management LLC boosted its position in shares of IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after purchasing an additional 37,734 shares in the last quarter. Bamco Inc. NY boosted its position in shares of IDEXX Laboratories by 4.3% during the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after purchasing an additional 82,264 shares in the last quarter. Invesco Ltd. boosted its position in shares of IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after purchasing an additional 74,324 shares in the last quarter. Norges Bank purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth $412,258,000. Finally, Northern Trust Corp boosted its position in shares of IDEXX Laboratories by 18.6% during the 4th quarter. Northern Trust Corp now owns 912,874 shares of the company's stock worth $377,419,000 after purchasing an additional 143,369 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director now owns 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Price Performance

IDXX stock traded up $15.19 during trading on Tuesday, hitting $516.76. The stock had a trading volume of 115,138 shares, compared to its average volume of 649,405. The company's 50 day moving average price is $442.28 and its two-hundred day moving average price is $435.02. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.60. The stock has a market cap of $41.56 billion, a price-to-earnings ratio of 48.34, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same quarter in the previous year, the company posted $2.71 EPS. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on IDXX shares. Stifel Nicolaus boosted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Finally, Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.